Greg Mayes Email & Phone Number

Mendham, NJ, US

Boston, Massachusetts, US

Atlanta, Georgia, US

Led $107m Series B financing; executed two alliance partnerships and acquired new novel agents in addition to guiding Hepatitis B therapeutics company through Phase 2 development

After successfully initiating and leading a $23M Series A investment round that included lead blue-chip investors TPG Biotech, Adage Capital and Lumira Ventures in Q4 2017 (raised $40M including 2019 follow-on with 100% of existing investor participation), launched late stage development company centered on an on-demand investigational product known as.

• Following a 2013 financial restructuring which included a 125:1 reverse stock split and up-listing to NASDAQ, joined new Executive Team in a multi-functional role leading business development, investor relations.
• Lead participant in all investor/analyst interface and fundraising efforts which has resulted in $275 million dollars raised to date (non-dilutive and dilutive capital);
• Secured analyst coverage (7 analysts have initiated coverage to date);
• Led all aspects of strategy and negotiation for $540 million dollar Global Cancer Immunotherapies license and stock purchase agreement with Amgen which resulted in a near term doubling of PPS and $65 million dollars in.
• Developed Phase 3 registration strategy and clinical development plan for AXAL(axalimogene filolisbac) resulting in FDA Special Protocol Assessment and Fast Track Designation.
• Beyond Amgen, executed an additional 5 worldwide licensing and commercial distribution agreements and 3 clinical collaboration agreements with major pharmaceutical companies;

Boonton, New Jersey, US

Responsible for all aspects of the Unigene Biotechnologies Business Unit, all legal oversight and administration of the Company’s day to day business operations as well as such duties and responsibilities as may be assigned by the Chief Executive Officer of the Company or the Board

US

• Lead 20-person Legal Department of a wholly-owned subsidiary of Eli Lilly and Company that develops and commercializes a portfolio of targeted anti-cancer treatments. Member of CEO’s Management Committee. Promoted four.
• Advising Board of Directors and Management Committee on all legal and governance matters, including litigation updates, securities filings and disclosure issues, FDA regulatory, employment, real estate and insurance.
• Overseeing patent and intellectual property strategy, prosecution, maintenance and related litigation;
• Drafting and negotiating license agreements and all forms of contracts necessary to support research and clinical development, manufacturing and commercial operation functions;
• Designing commercial sales policies and practices to comply with a myriad of federal and state laws;
• Managing eight-figure legal budget and relationships with outside legal counsel and domestic and international partnerships with Bristol-Myers Squibb and Merck KGaA; and

Cambridge, Cambridgeshire, GB

2003 – 2005 Responsibilities: Led the delivery of all legal services necessary for the U.S.-based breast cancer and prostate cancer brand teams to achieve their business objectives in compliance with applicable laws, regulations and corporate policies. Responsible for providing legal advice, including all facets of the Prescription Drug Marketing Act, to.

Philadelphia, PA, US

J.D. Magna Cum Laude, Business/Commerce, General

B.S. Cum Laude, Political Science, Advertising